TWI801737B - 輕度認知障礙改善用組成物及使用該組成物之輕度認知障礙的改善方法 - Google Patents
輕度認知障礙改善用組成物及使用該組成物之輕度認知障礙的改善方法 Download PDFInfo
- Publication number
- TWI801737B TWI801737B TW109119147A TW109119147A TWI801737B TW I801737 B TWI801737 B TW I801737B TW 109119147 A TW109119147 A TW 109119147A TW 109119147 A TW109119147 A TW 109119147A TW I801737 B TWI801737 B TW I801737B
- Authority
- TW
- Taiwan
- Prior art keywords
- cognitive impairment
- mild cognitive
- composition
- carnosine
- imidazole dipeptide
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 39
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000000284 extract Substances 0.000 claims abstract description 26
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 24
- 108010087806 Carnosine Proteins 0.000 claims abstract description 24
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940044199 carnosine Drugs 0.000 claims abstract description 24
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 22
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 20
- 241000972773 Aulopiformes Species 0.000 claims abstract description 12
- 235000019515 salmon Nutrition 0.000 claims abstract description 12
- 241000287828 Gallus gallus Species 0.000 claims abstract description 9
- 206010012289 Dementia Diseases 0.000 claims description 34
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 8
- 235000001785 ferulic acid Nutrition 0.000 claims description 8
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 8
- 229940114124 ferulic acid Drugs 0.000 claims description 8
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 8
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 8
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 4
- 235000013793 astaxanthin Nutrition 0.000 claims description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 4
- 229940022405 astaxanthin Drugs 0.000 claims description 4
- 239000001168 astaxanthin Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000006872 improvement Effects 0.000 abstract description 4
- 239000012535 impurity Substances 0.000 abstract 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 34
- 229940109239 creatinine Drugs 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000003078 antioxidant effect Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 8
- 229930003268 Vitamin C Natural products 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 235000019154 vitamin C Nutrition 0.000 description 8
- 239000011718 vitamin C Substances 0.000 description 8
- 230000007850 degeneration Effects 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 methyl carnosine Chemical compound 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 1
- 241000442132 Lactarius lactarius Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 108700002498 homocarnosine Proteins 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019-132196 | 2019-07-17 | ||
| JP2019132196A JP7321017B2 (ja) | 2019-07-17 | 2019-07-17 | 機能性食品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202116345A TW202116345A (zh) | 2021-05-01 |
| TWI801737B true TWI801737B (zh) | 2023-05-11 |
Family
ID=74343267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109119147A TWI801737B (zh) | 2019-07-17 | 2020-06-08 | 輕度認知障礙改善用組成物及使用該組成物之輕度認知障礙的改善方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20210015886A1 (https=) |
| JP (3) | JP7321017B2 (https=) |
| TW (1) | TWI801737B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024179725A (ja) * | 2023-06-15 | 2024-12-26 | 日本予防医薬株式会社 | イミダゾールジペプチドおよび黒大豆種皮抽出物を含有する組成物 |
| JP7714085B1 (ja) | 2024-05-10 | 2025-07-28 | 森永乳業株式会社 | 密封容器入り飲食品及び密封容器入り飲食品の製造方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000201649A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Meat Packers Inc | 皮膚代謝促進物及び機能性食品 |
| WO2002076455A1 (fr) * | 2001-03-16 | 2002-10-03 | Suntory Limited | Agents de regulation autonome et poissons et aliments dietetiques |
| JP2007070316A (ja) * | 2005-09-09 | 2007-03-22 | Nippon Meat Packers Inc | 経口用組成物及び栄養補助食品 |
| JP2014142910A (ja) * | 2012-12-28 | 2014-08-07 | Panasonic Corp | 制御装置、発電制御装置、太陽光発電システム、制御方法、及び発電制御方法 |
| CN106413733A (zh) * | 2014-03-28 | 2017-02-15 | 国立大学法人东京大学 | 包含咪唑二肽的试剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0920661A (ja) * | 1995-07-04 | 1997-01-21 | Suntory Ltd | 学習能力向上組成物 |
| WO2003013514A1 (en) | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| JP5089025B2 (ja) | 2004-04-30 | 2012-12-05 | 東海物産株式会社 | 抗酸化組成物 |
| JP5142126B2 (ja) | 2007-08-22 | 2013-02-13 | 東海物産株式会社 | 抗酸化性ジペプチドの製造方法 |
| JP2013526518A (ja) | 2010-05-13 | 2013-06-24 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Ｍｃｉおよびアルツハイマー病の処置 |
| KR101734645B1 (ko) | 2015-05-18 | 2017-05-11 | (주)에이엔티랩스 | 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법 |
| JP6550357B2 (ja) | 2016-08-24 | 2019-07-24 | 日本ハム株式会社 | イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤 |
| JP6934774B2 (ja) | 2016-12-27 | 2021-09-15 | 東海物産株式会社 | イミダゾールジペプチド合成活性を有するタンパク質及びイミダゾールジペプチドの製造方法 |
-
2019
- 2019-07-17 JP JP2019132196A patent/JP7321017B2/ja active Active
-
2020
- 2020-06-08 TW TW109119147A patent/TWI801737B/zh active
- 2020-07-17 US US16/931,979 patent/US20210015886A1/en not_active Abandoned
-
2023
- 2023-04-12 JP JP2023064666A patent/JP2023080213A/ja active Pending
- 2023-06-13 JP JP2023097266A patent/JP2023113933A/ja active Pending
- 2023-07-27 US US18/360,773 patent/US20230364180A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000201649A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Meat Packers Inc | 皮膚代謝促進物及び機能性食品 |
| WO2002076455A1 (fr) * | 2001-03-16 | 2002-10-03 | Suntory Limited | Agents de regulation autonome et poissons et aliments dietetiques |
| JP2007070316A (ja) * | 2005-09-09 | 2007-03-22 | Nippon Meat Packers Inc | 経口用組成物及び栄養補助食品 |
| JP2014142910A (ja) * | 2012-12-28 | 2014-08-07 | Panasonic Corp | 制御装置、発電制御装置、太陽光発電システム、制御方法、及び発電制御方法 |
| CN106413733A (zh) * | 2014-03-28 | 2017-02-15 | 国立大学法人东京大学 | 包含咪唑二肽的试剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230364180A1 (en) | 2023-11-16 |
| JP7321017B2 (ja) | 2023-08-04 |
| JP2023080213A (ja) | 2023-06-08 |
| TW202116345A (zh) | 2021-05-01 |
| US20210015886A1 (en) | 2021-01-21 |
| JP2021017402A (ja) | 2021-02-15 |
| JP2023113933A (ja) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011151632A1 (en) | Dietary formulations | |
| KR101172923B1 (ko) | 신경보호성 건강 보조식품 | |
| US20230364180A1 (en) | Composition for improving mild cognitive impairment and method for improving mild cognitive impairment | |
| JP2011111434A (ja) | 皮膚機能改善剤及びそれを含む飲食品 | |
| JP6735224B2 (ja) | アストロサイトのグルコース代謝活性化剤 | |
| JP5089025B2 (ja) | 抗酸化組成物 | |
| US20110268813A1 (en) | Preventing liver injury and improving liver function effects of ena-actimineral resources | |
| EP1575593A2 (de) | VERWENDUNG VON TETRAHYDROBIOPTERINDERIVATEN ZUR BEHANDLUNG UND ERN HRUNG VON PATIENTEN MIT AMINOS URESTOFFWECHSELST&Ouml ;RUNGEN | |
| Ramalingam et al. | Dietary UKMR-1 roselle supplementation prevents nicotine-induced cardiac injury by inhibiting myocardial oxidative stress | |
| JP2010105946A (ja) | 筋タンパク質増強剤及びこれを含む医薬品または食品 | |
| WO2017191838A1 (ja) | 安全・安定なプラズマローゲンとその製剤及び認知症の未病状態の判定方法 | |
| JP2005082495A (ja) | 脳細胞保護のための組成物 | |
| JP2017195830A (ja) | 脂肪蓄積予防用の食品組成物 | |
| JP5679966B2 (ja) | 皮膚機能改善組成物 | |
| Adebayo et al. | Protective effect of selenium on protein-undernutrition-induced brain damage in rats | |
| JP7016093B2 (ja) | 安全・安定なプラズマローゲンとその製剤及び認知症の未病状態の判定方法 | |
| JP7197701B2 (ja) | 脂肪形成抑制と抗酸化活性を有する組成物およびその用途 | |
| JP3713553B2 (ja) | アルギニンとｒｎａを含有する脳脊髄系神経栄養剤 | |
| US20090082269A1 (en) | Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same | |
| TWI745609B (zh) | 具抗氧化活性之組合物 | |
| EP4374708B1 (en) | Nutritional supplement preparation | |
| WO2025168966A1 (en) | Delphinidin-rich maqui berry composition as agent for increasing muscle mass and anti-aging agent | |
| CN110812383A (zh) | 具有抑制脂肪形成及抗氧化活性的组合物及其用途 | |
| JP2004115489A (ja) | 生体内の障害を緩和する機能性組成物 | |
| Gupta et al. | Taurine as drug and functional food component |